Alberto Souza, NP
Psychiatric/Mental Health · Saint George, UTNPI 1972846384
Payments from drug & device makers
Across 514 payments — averaging $222.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$80K
- Biogen$19K
- AbbVie$10K
- Teva Pharmaceuticals USA, Inc.$2K
- Axsome Therapeutics, Inc.$540
- Janssen Scientific Affairs, LLC$535
- plus $3K from 23 others
What the payments were for
- Consulting fees$1,5441%
- Speaking & faculty fees$91,25780%
- Travel & lodging$11,75410%
- Food & beverage$9,5948%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 153 | $79,968 |
| Biogen | 40 | $18,699 |
| AbbVie(2 entities) | 78 | $9,837 |
| Teva Pharmaceuticals USA, Inc. | 76 | $1,817 |
| Axsome Therapeutics, Inc. | 25 | $540 |
| Janssen Scientific Affairs, LLC | 10 | $535 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $378 |
| Otsuka America Pharmaceutical, Inc. | 15 | $365 |
| E.r. Squibb & Sons, L.L.C. | 15 | $298 |
| Indivior Inc. | 14 | $293 |
| Neurocrine Biosciences, Inc. | 11 | $279 |
| Alkermes, Inc. | 11 | $230 |
| Lundbeck LLC | 9 | $202 |
| Ironshore Pharmaceuticals Inc. | 5 | $111 |
| Braeburn Inc. | 5 | $94 |
| Idorsia Pharmaceuticals US Inc | 5 | $93 |
| USWM, LLC | 4 | $84 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $61 |
| Tris Pharma Inc | 3 | $56 |
| Boehringer Ingelheim | 2 | $48 |
| Corium, LLC | 2 | $37 |
| Sage Therapeutics, LLC | 1 | $28 |
| Tempus AI, Inc | 1 | $28 |
| Orphalan Inc | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$77,682
- Zurzuvae$17,951
- VRAYLAR$8,523
- UZEDY$990
- INVEGA SUSTENNA$139
How this compares
$114,207 in reported general payments places this provider in the 95th percentile of 393 psychiatric/mental health providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 58 | $82,148 |
| Bupropion XlBupropion Hcl | 55 | $5,873 |
| Duloxetine Hcl | 52 | $1,347 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 62 | $1,347 |
| Oxcarbazepine | 46 | $1,053 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 23 | $830 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 28 | $710 |
| Quetiapine Fumarate | 32 | $707 |
| Buspirone Hcl | 26 | $526 |
| Trazodone Hcl | 76 | $484 |
| Sertraline Hcl | 45 | $441 |
| Lamotrigine | 28 | $428 |
| Eszopiclone | 19 | $403 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $363 |
| Mirtazapine | 39 | $341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $365 | $82,14858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 393 psychiatric/mental health providers in Utah.
Other psychiatric/mental health in Saint George
- Paige MarshallSaint George$13K
- Jacob RobertsSaint George$5K
- Lori JardineSaint George$4K
- Clint MartineauSaint George$3K
- Bret HafenLayton$381K
- Anthony BrowningOrem$32K
- Debra HainRiverton$29K
- Kristin BarberSalt Lake City$28K
- Briana TerrySalt Lake City$14K
- Derick MoodySpringville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.